Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Dogwood Therapeutics Inc

DWTX ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.12

▼ -4.27%

Market Cap $38.07M · Vol 22.62K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$38.07M

Micro Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

+86.62%

YoY

RSI (14)

16.00

Momentum

Beta

2.09

vs Market

52W High

$7.04

83.38% below

52W Low

$1.11

2.63% above

Volume

22.62K

Avg 17.23K

P/B

1.65

Price-to-book

ROE

N/A

Return on equity

Free Float

27.43%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Dogwood Therapeutics Inc (DWTX) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does DWTX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-10.40%

-25.83%

-23.29%

-26.80%

YTD

-73.08%

-79.75%

-92.07%

-98.99%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-34,257,370.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-36.90% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.65
P/FCF	N/A
EPS Growth	+86.62%
Outstanding Shares	33.99M

Technical Indicators

50-Day SMA	$1.80
200-Day SMA	$2.03
RSI (14)	16.00
Beta	2.09
52-Week High	$7.04
52-Week Low	$1.11

Volume Today	22.62K
Avg Daily Volume (30D)	17.23K
Relative Volume	1.31x
Volatility (10D)	32.46
Volatility (30D)	50.13
Free Float	27.43%

Analyst Consensus

BUY

Current Price $1.12

Mean Target $13.50

52W Low$1.11 52W High$7.04

Current

Target

$1.11 $7.04

Current Analyst target

+1,105.36% upside potential · 2 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00X0SZLB8

ISINUS92829J2033

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -6.02% ARGX.BR argenx SE -0.41% ARGX argenx SE -1.61% GMAB.CO Genmab A/S +1.30% GMAB Genmab A/S +1.09%

Company Profile

Dogwood Therapeutics, Inc. is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).